➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Express Scripts
Colorcon
Merck

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

VIIBRYD Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in twenty-nine countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

Drug patent expirations by year for VIIBRYD
Drug Prices for VIIBRYD

See drug prices for VIIBRYD

Drug Sales Revenue Trends for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Forest LaboratoriesPhase 1
New York State Psychiatric InstitutePhase 4
Forest LaboratoriesPhase 3

See all VIIBRYD clinical trials

Paragraph IV (Patent) Challenges for VIIBRYD
Tradename Dosage Ingredient NDA Submissiondate
VIIBRYD TABLET;ORAL vilazodone hydrochloride 022567 2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Johnson and Johnson
AstraZeneca
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.